Preoperative imaging and prediction of oesophageal conduit necrosis after oesophagectomy for cancer. BJS 2017; 104: 1346-1354.
Published: 11th May 2017
Authors: P. Lainas, D. Fuks, S. Gaujoux, Z. Machroub, A. Fregeville, T. Perniceni et al.
Oesophageal conduit necrosis following oesophagectomy is a rare but life‐threatening complication. The present study aimed to assess the impact of coeliac axis stenosis on outcomes after oesophagectomy for cancer.
The study included consecutive patients who had an Ivor Lewis procedure with curative intent for middle‐ and lower‐third oesophageal cancer at two tertiary referral centres. All patients underwent preoperative multidetector
Some 481 patients underwent an Ivor Lewis procedure. Of these, ten (2·1 per cent) developed oesophageal conduit necrosis after surgery. Coeliac artery evaluation revealed a completely normal artery in 431 patients (91·5 per cent) in the group without conduit necrosis and in one (10 per cent) with necrosis (
This study suggests that oesophageal conduit necrosis after oesophagectomy for cancer may be due to pre‐existing coeliac axis stenosis.Read more
You may also be interested in
Effect of age on rates of palliative surgery and chemotherapy use in patients with locally advanced or metastatic gastric cancer.
Authors: S. D. Nelen, M. van Putten, V. E. P. P. Lemmens, K. Bosscha, J. H. W. de Wilt, R. H. A. Verhoeven et al.
Notes: Less surgery, more chemo, but no change in survival
Changes in treatment and outcome of oesophageal cancer in Denmark between 2004 and 2013. BJS 2017; 104: 1338-1345.
Authors: D. W. Kjaer, H. Larsson, L. B. Svendsen, L. S. Jensen
Notes: Better short‐term outcome
Randomized clinical trial
Randomized clinical trial of psychological support and sleep adjuvant measures for postoperative sleep disturbance in patients undergoing oesophagectomy. BJS 2017; 104: 1307-1314.
Authors: M. Scarpa, E. Pinto, E. Saraceni, F. Cavallin, M. Parotto, R. Alfieri et al.
Notes: Psychologists improve postoperative sleep
Adaptation of the By‐Band randomized clinical trial to By‐Band‐Sleeve to include a new intervention and maintain relevance of the study to practice. BJS 2017; 104: 1207-1214.
Authors: C. A. Rogers, B. C. Reeves, J. Byrne, J. L. Donovan, G. Mazza, S. Paramasivan et al.
Notes: Something to consider
Loss of SRY‐box2 (SOX2) expression and its impact on survival of patients with oesophageal adenocarcinoma. BJS 2017; 104: 1327-1337.
Authors: F. J. C. ten Kate, S. H. van Olphen, M. J. Bruno, B. P. L. Wijnhoven, J. J. B. van Lanschot, L. H. J. Looijenga et al.
Notes: Useful biomarker, especially for early disease
Authors: J. Thereaux, T. Lesuffleur, M. Païta, S. Czernichow, A. Basdevant, S. Msika et al.
Notes: Poor follow‐up despite international guidelines
Meta‐analysis of health‐related quality of life after minimally invasive versus open oesophagectomy for oesophageal cancer. BJS 2017; 104: 1131-1140.
Authors: J. H. Kauppila, S. Xie, A. Johar, S. R. Markar, P. Lagergren
Notes: Only different in short term
Authors: C. Lin, H. Liu, H. Zhang, Y. Cao, R. Li, S. Wu et al.
Notes: Tumour microenvironment is important
Corrigendum: Metabolic nodal response as a prognostic marker after neoadjuvant therapy for oesophageal cancer. BJS 2017; 104: 947-947.
Authors: J. M. Findlay, K. M. Bradley, L. M. Wang, J. M. Franklin, E. J. Teoh, F. V. Gleeson et al.
Validation of two prognostic models for recurrence and survival after radical gastrectomy for gastric cancer. BJS 2017; 104: 1235-1243.
Authors: M. Bencivenga, G. Verlato, D.‐S. Han, D. Marrelli, F. Roviello, H.‐K. Yang et al.
Notes: Good performance
Survival benefit of liver resection for Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma. BJS 2017; 104: 1045-1052.
Authors: H. Kim, S. W. Ahn, S. K. Hong, K. C. Yoon, H.‐S. Kim, Y. R. Choi et al.
Notes: Selected patients benefit
Validation of a nomogram for selecting patients for chemotherapy after D2 gastrectomy for cancer. BJS 2017; 104: 1226-1234.
Authors: Z.‐X. Wang, G.‐X. Li, Z.‐W. Zhou, Z.‐P. Huang, F. Wang, R.‐H. Xu et al.
Notes: Facilitates individualized treatment